blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3150203

EP3150203 - COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.12.2020
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  17.01.2020
FormerGrant of patent is intended
Status updated on  24.09.2019
FormerExamination is in progress
Status updated on  02.11.2018
FormerRequest for examination was made
Status updated on  06.10.2017
FormerThe application has been published
Status updated on  03.03.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Allianz Pharmascience Ltd
11F, No. 1 Songzhi Road
Xinyi Dist.
Taipei City 11047 / TW
[2017/14]
Inventor(s)01 / SHIH, Charles
153 S. Sierra Avenue, Unit 1473
Solana Beach, CA California 92075 / US
02 / SHI, Qian
153 S. Sierra Avenue, Unit 1473
Solana Beach, CA California 92075 / US
03 / WANG, Hui-Kang
153 S. Sierra Avenue, Unit 1473
Solana Beach, CA California 92075 / US
04 / SU, Ching-Yuan
3721 Boulder Ridge, DR.
Champaign, IL Illinois 61822 / US
 [2017/14]
Representative(s)Novagraaf Technologies
Bâtiment O2
2, rue Sarah Bernhardt
CS90017
92665 Asnières-sur-Seine Cedex / FR
[2017/14]
Application number, filing date16187672.717.06.2013
[2017/14]
Priority number, dateUS20121352594118.06.2012         Original published format: US201213525941
[2017/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3150203
Date:05.04.2017
Language:EN
[2017/14]
Type: B1 Patent specification 
No.:EP3150203
Date:19.02.2020
Language:EN
[2020/08]
Search report(s)(Supplementary) European search report - dispatched on:EP16.02.2017
ClassificationIPC:A61K31/121, A61P17/02, A01N35/02
[2017/14]
CPC:
A61K31/16 (EP,KR); C07C69/738 (CN); A61K31/121 (EP,KR);
A61K31/426 (EP,KR); A61K31/5375 (EP,KR); A61P17/00 (EP);
A61P17/02 (EP,KR); A61P17/10 (EP); A61P17/14 (EP,KR);
A61P21/00 (EP); A61P21/02 (EP); A61P29/00 (EP,KR);
A61P35/00 (EP,KR); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P5/28 (EP); C07C235/78 (CN);
C07C49/255 (CN); C07C59/90 (CN); C07D277/46 (CN);
C07D295/185 (CN) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/45]
Former [2017/14]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERBINDUNGEN MIT (1E,6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4,4-DISUBSTITUIERTEM-HEPA-1,6-DIEN-3,5-DI-ONE-STRUKTURGERÜST, DEREN BIOLOGISCHE AKTIVITÄT UND VERWENDUNGEN DAVON[2017/14]
English:COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF[2017/14]
French:COMPOSÉS AVEC (1E, 6E) -1,7-BIS- (3,4- DIMÉTHOXYPHÉNYL) -4,4-DISTRIBUÉ-HEPA-1,6-DIENE-3,5-DI-ONE, ÉCHAFAUDAGE STRUCTURAL, LEUR ACTIVITÉ BIOLOGIQUE ET LEURS UTILISATIONS[2017/14]
Examination procedure07.09.2016Date on which the examining division has become responsible
02.10.2017Amendment by applicant (claims and/or description)
02.10.2017Examination requested  [2017/45]
24.10.2018Despatch of a communication from the examining division (Time limit: M04)
08.02.2019Reply to a communication from the examining division
25.09.2019Communication of intention to grant the patent
18.12.2019Fee for grant paid
18.12.2019Fee for publishing/printing paid
18.12.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13806162.7  / EP2861222
Opposition(s)20.11.2020No opposition filed within time limit [2021/04]
Fees paidRenewal fee
07.09.2016Renewal fee patent year 03
07.09.2016Renewal fee patent year 04
09.06.2017Renewal fee patent year 05
29.06.2018Renewal fee patent year 06
28.06.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.06.2013
AL19.02.2020
AT19.02.2020
CY19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
MK19.02.2020
MT19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
TR19.02.2020
BG19.05.2020
GR20.05.2020
IE17.06.2020
LU17.06.2020
IS19.06.2020
PT12.07.2020
[2022/31]
Former [2022/30]HU17.06.2013
AL19.02.2020
AT19.02.2020
CY19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
MT19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
TR19.02.2020
BG19.05.2020
GR20.05.2020
IE17.06.2020
LU17.06.2020
IS19.06.2020
PT12.07.2020
Former [2022/27]HU17.06.2013
AT19.02.2020
CY19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
MT19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
TR19.02.2020
BG19.05.2020
GR20.05.2020
IE17.06.2020
LU17.06.2020
IS19.06.2020
PT12.07.2020
Former [2021/20]AT19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
IE17.06.2020
LU17.06.2020
IS19.06.2020
PT12.07.2020
Former [2021/15]AT19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
LU17.06.2020
IS19.06.2020
PT12.07.2020
Former [2021/11]AT19.02.2020
CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/50]CZ19.02.2020
EE19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
RO19.02.2020
RS19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/49]CZ19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
RO19.02.2020
RS19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/48]FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
RO19.02.2020
RS19.02.2020
SM19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/47]FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
RS19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
Former [2020/40]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
BG19.05.2020
GR20.05.2020
IS19.06.2020
Former [2020/39]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
BG19.05.2020
GR20.05.2020
Former [2020/38]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
GR20.05.2020
Former [2020/37]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
Former [2020/35]FI19.02.2020
Documents cited:Search[Y]WO03088927  (UNIV NORTH CAROLINA [US], et al) [Y] 1-9 * page 10, line 20 * * claims 8,13,28-30,32 *;
 [Y]WO2006044379  (UNIV NORTH CAROLINA [US], et al) [Y] 1-9 * claims 1,15-18,24-28 *;
 [Y]WO2008085984  (ANDROSCIENCE CORP [US], et al) [Y] 1-9 * claims 4,15-17 * * examples 1,2 * * figure 2 *;
 [Y]WO2009017815  (ANDROSCIENCE CORP [US], et al) [Y] 1-9 * figures 2,3A,3B * * claims 1,3-9,12-14 *;
 [Y]  - LIN L ET AL, "Antitumor Agents. 250. Design and Synthesis of New Curcumin Analogues as Potential Anti-Prostate Cancer Agents", JOURNAL OF MEDICINAL CHEMISTRY,, (20060701), vol. 49, no. 13, doi:10.1021/JM051043Z, pages 3963 - 3972, XP008110105 [Y] 1-9 * table 1 * * page 3967, column l, paragraph 1 * * page 3967, column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1021/jm051043z
 [Y]  - OHTSU H ET AL, "Antitumor agents 222. Synthesis and anti-androgen activity of new diarylheptanoids", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 11, no. 23, doi:10.1016/J.BMC.2003.08.029, ISSN 0968-0896, (20031117), pages 5083 - 5090, (20031014), XP008122579 [Y] 1-9 * figure 1 * * tables 1,2 *

DOI:   http://dx.doi.org/10.1016/J.BMC.2003.08.029
by applicant   - BIOCHEM., (1972), vol. 11, pages 942 - 944
    - PEDERSEN ET AL., LIEBIGS ANN. CHEM., (1985), pages 1557 - 1569
    - B. P. JOSHI ET AL., TETRAHEDRON, (2006), vol. 62, pages 2590 - 2593
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.